Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Afizzle will hit "critical mass" just about the same time that pigs with wings will be flying through snowstorms in Hell.
You can live with those year to year numbers??? Thing is, 50% of nothing is still nothing. And that is just about all that MNKD has to offer investors -- nothing.
"And Mannkind's TRAIL of PATHETIC performances continues with today's NEW SCRIPT NUMBERS:
Nrx = 235
Refills = 316
Trx = 551
Revenues = 837,000
LAST WEEK:
Nrx = 219
Refills = 271
Trx = 490
Revenues = 715,550"
Too hilarious! For $200 you can buy $2000 worth of afrezza -- if you're one of the first 1000 that join before the end of January.
Ought to cut into profit margins quite a bit, huh?
Afreeza??? What's "afreeza"? A place a Bostonian stores his leftovers?
LOL! Desperate situations call for desperate measures. You need to ask yourself how much of that $120 script will go to Eagle Pharmacy.
No, read it all for what it is -- DTC afizzle sales, reducing the number of territories from 44 to 30, reducing the number of sales reps, spending more and more on advertising -- all indications of how big a failure afizzle is.
Indeed, I wonder who IS making calmares these days. God knows CTTC still has four or five hundred it can't give away, so they aren't ordering any. Does ANYONE make calmares anymore?
Looks like The "painscrambler" is popular in Korea:
http://geomc.com/page/intro
Script numbers after four years on the market indicate it's closer to a BABboon for investors than any sort of a "boon" for diabetics.
Are you referring to this:
https://patientdaily.com/stories/511718551-inhaled-insulin-can-be-boon-to-diabetes-sufferers-says-jdrf
"The medication, with the brand name Afrezza, is a fast-acting insulin that complements other ways of introducing the hormone into the body."
That's pretty much what they've been saying the past four years.
Indeed, it looks like Smith abandoned ship altogether and moved on to a DIFFERENT "electrostimulation" AND a different company, "Piomed":
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162932/
"The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol"
And the patient just wears it like a wristwatch -- SO much more convenient!
Oh, my! Looks like their gizmo does all SORTS of stuff, doesn't it:
https://www.slideshare.net/PIOMED/piomed-inc-company-information
After the results of that last study, guess you can't blame him, huh?
ROFLMAO!!
Oh, you talking about this:
http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e22206
"A pilot randomized sham-controlled trial of MC5-A scrambler therapy in the treatment of chronic chemotherapy-induced peripheral neuropathy (CIPN)...
...Conclusions: We observed no difference between sham and real ST [scrambler thaerapy] treatment in CIPN."
My, that worked out WELL, didn't it!
Even more interesting is in the disclosures:
https://coi.asco.org/Report/ViewAbstractCOI?id=227731
"Thomas J. Smith...
Travel, Accommodations, Expenses - GeoMC"
What? No CTTC???
ROFLMAO!
ROFLMAO!!!
LOL! You got me thinking and I found an article about Smith's study:
https://blogs.bmj.com/bmj/2018/05/29/unreported-clinical-trial-of-the-week-scrambler-therapy-in-the-treatment-of-chronic-chemotherapy-induced-peripheral-neuropathy-nct02111174/
"Unreported clinical trial of the week: Scrambler therapy in the treatment of chronic chemotherapy-induced peripheral neuropathy (NCT02111174)
May 29, 2018
Nick DeVito and Ben Goldacre
Background
The US FDA Amendments Act (FDAAA 2007) requires certain clinical trials to report their results onto ClinicalTrials.gov within one year of completion. Our FDAAA TrialsTracker shows all individual trials that breach this legal requirement. Once a week, we write about one unreported clinical trial: you can read more background here..."
Yeah, that one just disappeared off the face of the earth, looks like!
"NEW SCRIPT NUMBERS:
Nrx = 203
Refills = 353
Trx = 558
Revenues =
LAST WEEK:
Nrx = 288
Refills = 312
Trx = 600
Revenues =
Revenues still pending"
LOL! Mannkind spending money on a cheap penny stock promoting youtube channel! Makes perfect sense!
SORRY!!! I wa s having trouble seeing the KEYBOARD through the TEARS from LAUGHING so HARD! HAW!
ROFMAO! I only just noticed that Friday CTTC closed at 4 cents a share -- over a 50% drop from Christmas eve -- on 5 times average volume. I guess Santa figured CTTC shareholders were ALL naughty.
"NEW SCRIPT NUMBERS:
Nrx = 381
Refills = 376
Trx = 757
Revenues = 1,117,200
LAST WEEK:
Nrx = 297
Refills = 344
Trx = 641
Revenues = 913,000"
Market overall showed a remarkable recovery from the days lows, but Mannkind still managed to close down 3 cents. The thing you have to wonder is WHAT will the CEO present in the conference next Friday that couldn't have been presented before the secondary?
I'm thinking it's going to be basically bad news with an attempt by the CEO to sugarcoat it with promises great things in the FUTURE. Anybody want to bet?
Trading below after hours. Not a whole lot of volume but very curious after such a big up day for the markets in general.
"Michael Kovocacy has changed his tune:
https://www.linkedin.com/feed/update/urn:li:activity:6482194921435516928
"What works better to kill a shareholder value unfriendly offering is a court injunction. Oh, but the courts are not really an option over the few business days before and around Christmas.
As I said numerous times yesterday, this offering is bad and sloppy in execution. Putting into the current market conditions is something that only the most desperate would do.
Now if there is a big catalyst that is time pressing and required this move, then one can just about swallow this rather untasty pill and the legal liability that will likely be coming.
But if this is just to refill the coffers for yet more of the same, then accountability will be the theme of 2019, not growth."
There's quite a bit more in his comments but there he seems to imply that MNKD was "desperate" and did the offering so close to the holidays in order to escape any possible legal action against it."
"Gotta LOVE it:
https://fdaheadlines.com/the-runway-equation-is-off-course-for-mannkind-corporation-nasdaqmnkd/
...the IMAGE alone is worth looking at!
You don't say:
"To us, this is a clear statement that the equation resulting from the UTHR deal is not working out when it comes to actually seeing the progress being made in a boots-on-the-ground sense."
Well, that's OBVIOUS enough!"
Wonder what kind of Christmas Conrad will celebrate this year.
Are you even aware of the secondary offering?
Now, be fair. After all he DIDN'T say what DIRECTION The "big move" would go.
"NEW SCRIPT NUMBERS:
Nrx = 297
Refills = 344
Trx = 641
Revenues = 913,000
LAST WEEK:
Nrx = 322
Refills = 404
Trx = 726
Revenues = 916,000"
Yeah, and isn't funny how many times it's been "a great time to buy back in" with MNKD? Thing is almost EVERY day seems like a great time to sell.
"MannKind Announces Commencement of Public Offering"
Oh, yes, definitely a "great time" to be buying:
https://finance.yahoo.com/news/mannkind-announces-commencement-public-offering-210100569.html
Down almost 20% after hours.
Good for a laugh -- neurologist using "calmar" therapy:
https://sunshineneurology.com/medical-services/#1448268456536-722ece38-0b79
Probably thanks God he can offer botox treatments to keep him fed.
Please, any "improvement" was just due to the rebound from the Thanksgiving
holiday. Nrx = 275 is especially pitiful when you consider how much they've been spending on commercials nationwide.
No, right now MNKD needs UTHR to say something about what it plans to do with tre-t. It was, what, 4-5 months ago that MNKD announced they had completed phase 1 and was ready to move directly to phase 3?
Then MNKD hands over complete control to UTHR and -- poof! -- it just disappears. No word from either MNKD or UTHR about what and/or when the next step will take place.
The only thing we know is that there ten other drugs ahead of tre-t in the approval pipeline. Fat lot of good that does MNKD.
Close? RLS is at least four years from anything. Tre-t ranks tenth on UTHR's launch list, far behind the pumps they're working on. Afrezza is stuck on its treadmill and still doesn't have Medicare coverage and still has worse than mediocre insurance coverage and they still aren't doing anything to change any of that.
About the only thing close is tax loss selling! Ho, ho, ho!
Too hilarious! Afrezzaguy doesn't tweet anything since May, then someone on proboards MNKD forum asks if he's died since he hasn't been doing his usual 2-3 tweets a day pumping afrezza and lo and behold there he is back to his 3 a day quota!
"NEW SCRIPT NUMBERS:
Nrx = 214
Refills = 303
Trx = 517
Revenues = 733,000
LAST WEEK:
Nrx = 274
Refills = 365
Trx = 639
Revenues = 899,000"
"NEW SCRIPT NUMBERS:
Nrx = 274
Refills = 365
Trx = 639
Revenues = 899,000
LAST WEEK:
Nrx = 251
Refills = 363
Trx = 614
Revenues = 866,000"
"NEW SCRIPT NUMBERS:
Nrx = 251
Refills = 363
Trx = 614
Revenues = 866,000
LAST WEEK:
Nrx = 299
Refills = 317
Trx = 616
Revenues = 873,000"
"Today's deal between ARNA and UTHR kind of gives a way of viewing United's opinion of Treprostinil-technosphere:
"Under the terms of the agreement, ARNA will receive $800M upfront, up to $400M in milestones and tiered low double-digit royalties on net sales."
And ralinepag phase 3 results aren't even expected until December of 2021.
Would appear UTHR values ralinepag a lot more, doesn't it?"
Yeah, I hear their negotiating with Tinker Bell to develop technosphere-fairy dust.
"NEW SCRIPT NUMBERS:
Nrx = 299
Refills = 317
Trx = 616
Revenues = 873,000
LAST WEEK:
Nrx = 275
Refills = 329
Trx = 604
Revenues = 808,000"
"What I think one should at least WONDER about is the status of treprostinil-technosphere.
The successful phase 1 trial was announced June 1:
http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-
successfully-completes-phase-1-trial-treprostinil
...which reassured naive investors:
"The regulatory and development pathway is expected to be capital efficient, using existing safety data of the component API to reduce Phase 3 requirements to a pivotal safety and efficacy trial and a pivotal bioequivalency trial. The regulatory submission in the United States is expected to utilize the 505(b)(2) pathway."
...implying further development would be a cinch for MNKD -- just like they said epinephrine-technosphere was going to be a "breeze" to get past the FDA.
Nevertheless, MNKD turns around on September 4th and basically GIVES tre-t away to UTHR:
https://www.genengnews.com/news/united-therapeutics-to-co-develop-mannkinds-dry-powder-treprostinil-for-pah/
...giving UTHR complete control:
"Under their worldwide exclusive licensing and collaboration agreement, United Therapeutics agreed to oversee global development, regulatory, and commercial activities involving treprostinil—while MannKind agreed to manufacture clinical supplies and initial commercial supplies of the product at its manufacturing facility in Danbury, CT."
FTC clearance came October 15:
https://www.nasdaq.com/press-release/united-therapeutics-and-mannkind-announce-closing-of-license-and-collaboration-agreement-20181016-00203
"As previously announced, the effectiveness of the agreement was conditioned upon expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The requisite waiting period expired on October 15, 2018, and the agreement became effective the same day."
But THEN not ONE word about further development plans was said at EITHER the Mannkind OR the United Therapeutics conferences.
To ME, that seems a bit STRANGE given all the brouhaha about the initial deal. One would think they would have ALREADY had discussions with the FDA and would have been ready to hit the ground RUNNING with a clinical trial once FTC approval arrived. "